<DOC>
	<DOC>NCT00149968</DOC>
	<brief_summary>The purpose of this study is to assess whether a switch from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI- and/or health-related quality of life outcomes, and to determine the proportion of renal transplant recipients who are experiencing any GI complaints under MMF-based immunosuppressive treatment.</brief_summary>
	<brief_title>Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Received kidney transplant at least 3 months prior to study enrollment Receiving immunosuppressive regimen that includes MMF in combination with other immunosuppressive drugs Receiving MMF for at least 1 month prior to enrollment Patients with any known hypersensitivity against mycophenolic acid, mycophenolate sodium, mycophenolate mofetil or other components of the formulations (e.g. lactose; see also summary of product characteristics of ECMPS) If applicable, GI symptoms assumed or known not to be caused by MPA therapy (e.g. oral biphosphonates induced, infectious diarrhea) Acute rejection &lt; 1 week prior to study enrollment Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>MMF</keyword>
	<keyword>EC-MPS</keyword>
	<keyword>GI problems</keyword>
</DOC>